FPS
RNAM

Fieldpoint Private Securities’s Avidity Biosciences RNAM Stock Holding History

Fieldpoint Private Securities’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-75
Closed -$2K – 1632
2021
Q1 		$2K Buy
+75
New +$1.84K ﹤0.01% 1401

Other funds holding RNAM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Fieldpoint Private Securities's RNAM Position: Q2 2021 in Review

Fieldpoint Private Securities sold out of Avidity Biosciences (RNAM) in Q2 2021, closing a stake of 75 shares — an estimated $2K sold.

Fieldpoint Private Securities first reported a position in RNAM in Q1 2021 and held it in 1 quarter. The position peaked at $2K in Q1 2021. 95 funds tracked by Wall St. Rank hold RNAM as of Q2 2021.

  • Fieldpoint Private Securities reported no remaining Avidity Biosciences position as of Q2 2021 after selling out during the quarter.
  • Fieldpoint Private Securities sold 75 Avidity Biosciences shares in Q2 2021, an estimated $2K.
  • Fieldpoint Private Securities first reported a position in Avidity Biosciences in Q1 2021 and held it in 1 quarter.
  • Fieldpoint Private Securities's Avidity Biosciences position peaked at $2K in Q1 2021.
  • 95 funds tracked by Wall St. Rank held Avidity Biosciences as of Q2 2021.

Based on Fieldpoint Private Securities's 13F filing for Q2 2021, filed 12 Aug 2021.